Phosphodiesterase inhibitors for treatment of voiding dysfunction: An overview of experimental and clinical evidence |
| |
Authors: | Ricardo Reges Rommel Prata Regadas Jo o Batista Gadelha Cerqueira Lú cio Flá vio Gonzaga-Silva |
| |
Affiliation: | Ricardo Reges, Rommel Prata Regadas, João Batista Gadelha Cerqueira, Lúcio Flávio Gonzaga-Silva, Division of Urology, Universidade Federal of Ceara, Fortaleza, Ceara 60160-070, Brazil |
| |
Abstract: | Recently,the focus of the origin of lower urinary tract symptoms(LUTS)has change from the prostate to the bladder.Regardless of the underlying mechanism associated with the origin of LUTS,alpha-blockers continue to be the most common medicine prescribed to treat LUTS due to benign prostatic obstruction(BPO).The newest class of drug introduced to treat LUTS/BPO is phosphodiesterase inhibitors(PDEi)and the aim of this study was to review the role of PDEi in the treatment of LUTS/BPO.In this review,the first evidence was evaluated based on epidemiological studies followed by randomized clinical trials which provide evidence on the administration of PDEi in patients with LUTS/BPO.Experimental studies were also assessed to tentatively elucidate the association between LUTS and erectile dysfunction,and to elucidate the underlying mechanism.There is still controversy regarding the administration of PDEi due to the fear of detrusorimpairment,response to acute administration,and the effects of PDEi combined with alpha-blockers.Following this review,we conclude that treatment of BPO/LUTS with PDEi is beneficial,based on experimental studies,strong evidence and the large number of randomized clinical trials confirming their efficiency. |
| |
Keywords: | Benign prostatic hyperplasia Lower urinary tract symptoms Phosphodiesterase inhibitor Mechanism of action Urodynamics |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《World Journal of Clinical Urology》浏览原始摘要信息 |
|